Blog
RSS FeedPosted by Michael Wonder on 19 May 2022
COVID-19 vaccine weekly safety report (19 May 2022)
19 May 2022 - To 15 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 13 May 2022
TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for children aged 6 months to 5 years old
13 May 2022 - The TGA has received, and immediately commenced evaluation of, an application from Moderna to extend the ...
Posted by Michael Wonder on 13 May 2022
TGA removes age limit for BBIBP-CorV (Sinopharm) COVID-19 vaccine recognition for international travel to Australia
13 May 2022 - The TGA has determined that the BBIBP-CorV (Sinopharm) COVID-19 vaccine will be 'recognised' for all ages for ...
Posted by Michael Wonder on 12 May 2022
ATAGI update following weekly COVID-19 meeting (11 May 2022)
12 May 2022 - On Wednesday 11 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 12 May 2022
COVID-19 vaccine weekly safety report (12 May 2022)
12 May 2022 - To 8 May 2022, the TGA has received 554 reports which have been assessed as likely to ...
Posted by Michael Wonder on 11 May 2022
ATAGI update following weekly COVID-19 meeting (4 May 2022)
9 May 2022 - On Wednesday 4 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 09 May 2022
Product information update for COVID-19 treatment Xevudy (sotrovimab)
6 May 2022 - On 7 April 2022, the TGA announced receipt of an application from GSK for a higher (1000 ...
Posted by Michael Wonder on 28 Apr 2022
COVID-19 vaccine weekly safety report (28 April 2022)
28 April 2022 - To 24 April 2022, the TGA has received 544 reports which have been assessed as likely to ...
Posted by Michael Wonder on 28 Apr 2022
TGA grants provisional determination for the Moderna bivalent COVID-19 vaccine "Spikevax Bivalent Zero/Omicron"
28 April 2022 - On 27 April 2022, the TGA granted a provisional determination to Moderna in relation to its ...
Posted by Michael Wonder on 21 Apr 2022
COVID-19 vaccine weekly safety report (24 April 2022)
24 April 2022 - To 17 April 2022, the TGA has received 534 reports which have been assessed as likely to ...
Posted by Michael Wonder on 14 Apr 2022
COVID-19 vaccine weekly safety report (14 April 2022)
14 April 2022 - To 10 April 2022, the TGA has received 528 reports which have been assessed as likely to ...
Posted by Michael Wonder on 09 Apr 2022
ATAGI statement on use of booster doses in adolescents aged 12-15 years
8 April 2022 - A statement from the ATAGI on booster doses in adolescents aged 12-15 years. ...
Posted by Michael Wonder on 08 Apr 2022
TGA provisionally approves Pfizer’s COVID-19 vaccine (Comirnaty), for use as a booster for individual aged 12–15 years old
8 April 2022 - The TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, Comirnaty, for use as a ...
Posted by Michael Wonder on 07 Apr 2022
TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (Xevudy) for the BA.2 omicron sublineage
7 April 2022 - The TGA has received an application from GSK for a higher (1,000 mg) dose of its ...
Posted by Michael Wonder on 07 Apr 2022
COVID-19 vaccine weekly safety report (7 April 2022)
7 April 2022 - To 3 April 2022, the TGA has received 511 reports which have been assessed as likely to ...